aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update
aTyr Pharma reported Q1 2026 results with a net loss of $10.8 million, a significant improvement from the $14.9 million loss in the same period last year, driven by lower R&D and G&A expenses. The company ended the quarter with $68.3 million in cash and investments, providing a runway for continued development activities. Following a Type C meeting with the FDA, aTyr outlined a clear path forward for its lead asset efzofitimod in pulmonary sarcoidosis, planning to submit an IND in June 2026 for a new Phase 3 study utilizing FVC as the primary endpoint.
Key figures
- Revenue
- 0
- Net loss
- 10791000
- Ga expenses
- 4100000
- Rd expenses
- 7300000
- Shares outstanding
- 98043839
- Cash and investments
- 68300000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.